ArticleFrontiers in pharmacology2022

A randomized, double-blind, placebo-controlled phase I trial of inhalation treatment of recombinant TFF2-IFN protein: A multifunctional candidate for the treatment of COVID-19.

Yan Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.